Edgestream Partners L.P. Invests $5.44 Million in DaVita Inc. (NYSE:DVA)

Edgestream Partners L.P. bought a new position in DaVita Inc. (NYSE:DVA) during the 3rd quarter, HoldingsChannel.com reports. The fund bought 33,188 shares of the company’s stock, valued at approximately $5,441,000.

Several other institutional investors have also made changes to their positions in the company. Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of DaVita in the third quarter worth approximately $1,820,000. PDT Partners LLC increased its position in shares of DaVita by 25.8% in the third quarter. PDT Partners LLC now owns 26,887 shares of the company’s stock worth $4,408,000 after acquiring an additional 5,506 shares in the last quarter. Verition Fund Management LLC increased its position in shares of DaVita by 313.6% in the third quarter. Verition Fund Management LLC now owns 9,603 shares of the company’s stock worth $1,574,000 after acquiring an additional 7,281 shares in the last quarter. Captrust Financial Advisors increased its position in shares of DaVita by 16.6% in the third quarter. Captrust Financial Advisors now owns 3,992 shares of the company’s stock worth $654,000 after acquiring an additional 569 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of DaVita by 22.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 114,166 shares of the company’s stock worth $18,715,000 after acquiring an additional 20,782 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Barclays raised their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. UBS Group raised their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Bank of America raised their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. Finally, Truist Financial raised their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, DaVita presently has a consensus rating of “Hold” and an average target price of $161.80.

DaVita Price Performance

Shares of DaVita stock opened at $166.17 on Friday. The firm has a fifty day simple moving average of $158.57 and a 200-day simple moving average of $149.31. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. DaVita Inc. has a 1-year low of $99.18 and a 1-year high of $169.51. The stock has a market capitalization of $13.63 billion, a price-to-earnings ratio of 17.93, a PEG ratio of 0.94 and a beta of 0.89.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same period last year, the firm posted $2.85 EPS. The company’s revenue was up 4.6% compared to the same quarter last year. On average, sell-side analysts expect that DaVita Inc. will post 9.71 earnings per share for the current year.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 9,881 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $162.85, for a total value of $1,609,120.85. Following the sale, the chief executive officer now owns 887,835 shares of the company’s stock, valued at $144,583,929.75. The trade was a 1.10 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 2.00% of the stock is currently owned by insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.